Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 91832-40-5
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/P,D/A,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
CAS NO:: |
91832-40-5 |
Appearance:: |
White Powder |
Molecular Formula:: |
C14H13N5O5S2 |
Molecular Weight:: |
395.41400 |
EINECS NO:: |
643-088-1 |
MDL NO:: |
MFCD00865030 |
CAS NO:: |
91832-40-5 |
Appearance:: |
White Powder |
Molecular Formula:: |
C14H13N5O5S2 |
Molecular Weight:: |
395.41400 |
EINECS NO:: |
643-088-1 |
MDL NO:: |
MFCD00865030 |
Product Description:
Product Name: Cefdinir CAS NO: 91832-40-5
Synonyms:
CI 983;
Novacef;
Omnice;
Chemical & Physical Properties:
Appearance: White powder
Assay :≥99.00%
Density: 1.89 g/cm3
Melting Point: >180℃ dec
Refractive Index: 1.861
Storage Condition: Room temp
Water Solubility: Soluble in water
Safety Information:
RTECS: XI0367250
HS Code: 2941905990
WGK Germany: 3
A Cephalosporin antibiotic structurally similar to Cefixime. Cefdinir (Omnicef) is a semi-synthetic, broad-spectrum antibiotic, which is proved to be effective for common bacterial infections of the ear, sinus, throat, and skin.Target: AntibacterialCefdinir is a third generation oral cephalosporin antibiotic. Cefdinir (Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, which is proved to be effective for common bacterial infections of the ear, sinus, throat, and skin. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria. It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark and Cefdiel by Ranbaxy. As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.Cefdinir, a new oral 2-amino-5-thiazolyl cephalosporin, inhibited the luminol-amplified chemiluminescence (LACL) response of human neutrophils stimulated by PMA but not opsonized zymosan, in a concentration-dependent but not time-dependent manner. The LACL response to opsonized zymosan in cytochalasin B-treated neutrophils was, however, inhibited by cefdinir. Furthermore, cefdinir inhibited LACL generation in cell-free systems consisting of H2O2, NaI, and either horseradish peroxidase or a myeloperoxidase-containing neutrophil extract. Orthodianisidine oxidation in these two acellular systems was inhibited by cefdinir.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.